Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer

Acta Oncologica

Volumn 49, Issue 7, 2010, Pages 888-894

  Ishkanian, Adrian S ^a,b   Zafarana, Gaetano ^b   Thoms, John ^a,b   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR ERG;

CANCER RADIOTHERAPY; CANCER RISK; CELL DEATH; CELL RENEWAL; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA REPAIR; HUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; REVIEW; SOMATIC MUTATION;

ALGORITHMS; ANIMALS; CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 77956584765     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.499371     Document Type: Review

References (24)

1. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Cancer Network 2010;8:162-200.
2. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues. Cancer 2005;104:891-905.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974 (Pubitemid 28445094)
4. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27: 4321-4326
5. Van Der Kwast TH, Evans A, Lockwood G, Tkachuk D, Bost-wick DG, Epstein JI, et al. Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol 2010;34:169-177
6. Ahmed HU, Pendse D, Illing R, Allen C, van Der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Natl Clin Pract Oncol 2007;4:632-642
7. Roach M, 3rd, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009;115(13 Suppl):3112-3120
8. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-531
9. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007;67: 8229-8239 (Pubitemid 47395160)
10. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275(5308):1943-1947
11. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-648
12. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36: 299-303.
13. Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, et al. High-resolution array CGH identifi es novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-1100
14. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-8510
15. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8: 180-192
16. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiother Oncol 2007;83: 220-230 (Pubitemid 46915541)
17. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1: 315-322
18. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993-999
19. Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008;86:407-411
20. Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010;102:570-576
21. Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 2009;19: 82-91.
22. Burri J, Haldimann M, Dudler V. Selenium status of the Swiss population: Assessment and change over a decade. J Trace Elem Med Biol 2008;22:112-119
23. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006;12:2545-2554
24. Pugh TJ, Keyes M, Barclay L, Delaney A, Krzywinski M, Thomas D, et al. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachy-therapy patients. Clin Cancer Res 2009;15:5008-5016